doi: 10.1038/s41366-023-01321-5
Some note only subtle improvements, and a few see no change at all
Those distinctions are exactly the kind of current, compound-specific detail a responsible clinician must verify rather than assume
switching formats later is also possible if the first choice does not fit
the appetite-suppressing effects of GLP-1 agonists require careful consideration Medication absorption : Delayed gastric emptying may theoretically affect the absorption of oral Crohn's disease medications, though clinical significance remains unclear Ongoing monitoring strategies include: Symptom diary : Patients should maintain records distinguishing new gastrointestinal symptoms from their baseline Crohn's pattern Faecal calprotectin testing : When clinically indicated to differentiate inflammatory activity from functional symptoms, in line with NICE DG11 guidance Nutritional surveillance : Regular assessment of weight, body composition, and nutritional markers (albumin, vitamins, minerals) Dose titration : Slower than standard dose escalation may improve gastrointestinal tolerability Collaborative care between gastroenterology and diabetes/obesity services is strongly recommended
doi: 10.1016/j.molmet.2017.06.015